<?xml version="1.0" encoding="UTF-8"?>
<p>More recently, it has been reported that ivermectin inhibits SARS‐CoV‐2 with an ~5000‐fold reduction in viral RNA after 48 hours.
 <xref rid="rmv2143-bib-0099" ref-type="ref">
  <sup>99</sup>
 </xref> Ivermectin is a FDA‐approved antiparasitic molecule, initially identified as an inhibitor of HIV protein nuclear import.
 <xref rid="rmv2143-bib-0118" ref-type="ref">
  <sup>118</sup>
 </xref> Its broad‐spectrum antiviral activity was documented in vitro.
 <xref rid="rmv2143-bib-0119" ref-type="ref">
  <sup>119</sup>
 </xref>, 
 <xref rid="rmv2143-bib-0120" ref-type="ref">
  <sup>120</sup>
 </xref> Ivermectin perturbs nuclear import through IMPα/β1; however, the role of this machinery during the CoV life cycle has not been elucidated yet. Nevertheless, an observational study reported survival benefits during hospitalization,
 <xref rid="rmv2143-bib-0121" ref-type="ref">
  <sup>121</sup>
 </xref> but no data on viral load, highlighting the necessity to validate this observation in clinical trials. Recent review presents the pharmacokinetic properties of ivermectin, and highlights that the dose currently used for parasitic disease do not effective against SARS infection.
 <xref rid="rmv2143-bib-0122" ref-type="ref">
  <sup>122</sup>
 </xref>
</p>
